LYON, France — The drug zodasiran , which targets the production of a liver protein, substantially lowers triglyceride and a range of lipoprotein levels in patients with mixed hyperlipidemia who are stable on optimal statin therapy, according to"The reductions in serum lipids and lipoproteins and the favorable safety profile seen in ARCHES-2 support the potential for zodasiran to treat residual atherosclerotic cardiovascular disease in patients with elevated triglycerides," said...
The combination of reductions in triglycerides, low-density lipoprotein cholesterol, remnant cholesterol, and apolipoprotein B, among others, should be"based on our current knowledge, decrease the cardiovascular risk of patients with mixed dyslipidemia quite significantly," he said. However, the progress seen with zodasiran and other siRNA-based therapies"highlights the importance of studying diverse populations because exceptional alleles are variably prevalent across racial and ethnic groups," he pointed out., are enabling the critical search of such exceptional alleles at an unprecedented scale," Natarajan explained."Inclusive human genetic research benefits us all.
As expected, all three doses of zodasiran were associated with"substantial and durable" reductions in ANGPTL3 levels from baseline, with a least-squares mean difference relative to placebo at 24 weeks of 54% with the 50-mg dose, 70% with the 100-mg dose, and 74% with the 200-mg dose, which were largely retained at 36 weeks.